Ned Bittinger

The Business Side of Art

This content shows Simple View

Cancer Research

Clay Siegall Expands Seattle Genetics

The pharmaceutical industry is a very important industry that is responsible for creating medications and processes that can help to save and improve lives. One individual that has dedicated his career to this industry is Clay Siegall who is the co-founder of Seattle Genetics. Clay Siegall helped to found the company in 1998 and today is the President and CEO of the company.

When he first founded the organization, his goal was to improve processes that are completed to treat a variety of different ailments and diseases. Today, the company is one of the leading of its kind and has formed a variety of joint ventures with some of the top companies in the pharma industry.

While Seattle Genetics has done a lot of great things by developing new drugs and medical procedures, the company has also been a great company for investors. Ever since the company was founded, Clay Siegall has helped the organization raise more than $1.8 billion in equity that has been used to expand the company and invest in the operations. The company has continued to raise a lot of capital and could see a major infusion or investment in the future as well.

The Seattle based company has done very well financially over the past decade and has continued to be showcased in a variety of magazines and professional newsletters due to the success that it has had. Along with this, it has continued to gain the attention of venture capitalists and even larger firms that are looking to expand.

While the company has been a leader for years, one of the most promising things about the firm is the growth that it is continuing to have. In 2016, the company made more than $418 million in revenue. This was a 45 percent increase from just two years prior. At the same time, the underlying stock value of the company has seen a 50% increase and is looking to continue to increase in the future.

Many stock analysts have continued to be very bullish on the company due to the strong potential it provides to investors. As the company continues to develop new technologies and change the pharma landscape, it will continue to be a very popular and intriguing target for those that are looking to expand on their footprint. Beyond the potential for a buyout, there is also a lot of potential for internal growth.

Plight of Dr. Clay Siegall

Most successful people didn’t start out success in life. For most of these individuals, failure was not an option. It takes patience as well as perseverance when trying to reach your goals and like the old saying goes, “Rome Wasn’t Built In A Day.” The fact is truly this and only this; anything worth having is worth working hard for. Unless you’re born into a wealthy family and just randomly hit the lottery, there will surly indeed be some form of plight to get you where you want to be. Clay Siegall is one of the most well respected individuals in cancer research. This guy has done it all as well as seen it all. Cancer has a way of bringing the best out of people especially those who are doing all they can to eradicate the illness.

Dr. Clay Siegall is at the of his game and has a huge level of success to back up all claims. With a (BS) in Zoology from The University of Maryland and a Ph.D from George Washington University, he has taken Seattle Genetics straight to the top. Seattle Genetics is huge with while holding an 800+ employee base. The growth of this company is that it produces the highest quality of cancer medications. The medications that are known as antibody drug conjugates, yield a much higher success rate than previous medications of the past. Dr. Siegall has built a solid foundation that stands by drug development, scientific innovation, and thorough research. There is no room for error when a person’s life is at stake and this company firmly stands by those principles.

As of 2015, Seattle Genetics has racked up over $226 Million from it’s (ADCETRIS) drug alone. This is just in Canada and the U.S. Expectations for the following year is somewhere between $250-$275 Million as this goes to show just how important these breakthrough therapies really are. Though Clay Siegall has come along way, he’s looking to take this company even farther in the years to come.